Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia
Open Access
- 8 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (6), 929-941
- https://doi.org/10.1093/hmg/ddab296
Abstract
Dominant GNAO1 mutations cause an emerging group of childhood-onset neurological disorders characterized by developmental delay, intellectual disability, movement disorders, drug-resistant seizures, and neurological deterioration. GNAO1 encodes the α-subunit of an inhibitory GTP/GDP-binding protein regulating ion channel activity and neurotransmitter release. The pathogenic mechanisms underlying GNAO1-related disorders remain largely elusive and there are no effective therapies. Here, we assessed the functional impact of two disease-causing variants associated with distinct clinical features, c.139A > G (p.S47G) and c.662C > A (p.A221D), using Caenorhabditis elegans as a model organism. The c.139A > G change was introduced into the orthologous position of the C. elegans gene via CRISPR/Cas9, whereas a knock-in strain carrying the p.A221D variant was already available. Like null mutants, homozygous knock-in animals showed increased egg laying and were hypersensitive to aldicarb, an inhibitor of acetylcholinesterase, suggesting excessive neurotransmitter release by different classes of motor neurons. Automated analysis of C. elegans locomotion indicated that goa-1 mutants move faster than control animals, with more frequent body bends and a higher reversal rate, and display uncoordinated locomotion. Phenotypic profiling of heterozygous animals revealed a strong hypomorphic effect of both variants, with a partial dominant-negative activity for the p.A221D allele. Finally, caffeine was shown to rescue aberrant motor function in C. elegans harboring the goa-1 variants; this effect is mainly exerted through adenosine receptor antagonism. Overall, our findings establish a suitable platform for drug discovery, which may assist in accelerating the development of new therapies for this devastating condition, and highlight the potential role of caffeine in controlling GNAO1-related dyskinesia.Funding Information
- Italian National Institute of Health (2020-2022_ISS20-0ab01a06bd2a)
- National Research Council (NUTR-AGE-FOE2019-DSB.AD004.271)
This publication has 85 references indexed in Scilit:
- Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegansLongevity & Healthspan, 2012
- Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's diseaseBrain Research, 2011
- Molecular architecture of Gα o and the structural basis for RGS16-mediated deactivationProceedings of the National Academy of Sciences of the United States of America, 2008
- Regulation of Serotonin Biosynthesis by the G Proteins Gαo and Gαq Controls Serotonin Signaling inCaenorhabditis elegansGenetics, 2008
- Analysis of synaptic transmission in Caenorhabditis elegans using an aldicarb-sensitivity assayNature Protocols, 2006
- Presynaptic UNC-31 (CAPS) Is Required to Activate the Gαs Pathway of the Caenorhabditis elegans Synaptic Signaling NetworkGenetics, 2006
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Serotonin Inhibition of Synaptic Transmission: Gαo Decreases the Abundance of UNC-13 at Release SitesNeuron, 1999
- Caffeine inhibits inositol-trisphosphate-induced membrane potential oscillations inXenopusoocytesProceedings. Biological sciences, 1991
- The structure of the ventral nerve cord of Caenorhabditis elegansPhilosophical Transactions of the Royal Society of London. B, Biological Sciences, 1976